Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Antigens in Healthy Adults
NCT04144179Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2019
- Primary completion
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Quadrivalent recombinant influenza vaccine in influenza (5 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate adverse events at 30 minutes, Number of participants with solicited injection site or systemic reactions and 7 more. Started Nov 2019; status: completed.
02
Drugs
Quadrivalent recombinant influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04144179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04144179.